Low rate of patient monitoring found following initiation of therapy for heart failure
Although frequent laboratory monitoring of patients with heart failure following initiation of mineralocorticoid receptor antagonists is supported by the results of large clinical trials and recommended in guidelines, there appears to be low rates of monitoring in clinical practice, according to a study in the November 10 issue of JAMA. This issue, a cardiovascular disease theme issue, coincides with the American Heart Association's Scientific Sessions 2015. Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of heart failure therapy but carry a risk of hyperkalemia (elevated potassium in the blood). Clinical guidelines recommend close monitoring of kidney function and electrolyte (including potassium) levels throughout the course of therapy. No large studies have examined whether laboratory monitoring occurs routinely in community practice. Adrian F. Hernandez, M.D., M.H.S., of the Duke University School of Medicine, Durham, N.C., and colleagues analyzed a group of patients (10,443 Medicare beneficiaries) with heart failure who had initiated MRA therapy (eplerenone or spironolactone). The researchers examined the frequency of measurement of serum creatinine and potassium levels before and after MRA initiation.
The researchers found that combined, 756 patients (7 percent) received appropriate testing before and after MRA initiation. After initiation of MRA therapy, 13 percent and 30 percent of patients received appropriate testing in early and extended follow-up, respectively. In contrast, 55 percent and 22 percent received no testing in early or extended follow-up, respectively. Atrial fibrillation, anemia, chronic kidney disease, chronic obstructive pulmonary disease, hypothyroidism, osteoporosis, and use of diuretics were associated with a greater likelihood of appropriate laboratory testing during all periods.
"The landmark trials of MRAs in heart failure showed MRAs significantly reduced mortality and cardiovascular readmission compared with placebo. However, an analysis of community practice found similar outcomes among patients treated or not treated with an MRA. One possible explanation may be less rigorous monitoring outside clinical trial settings, which may increase risks of adverse events associated with MRAs," the authors write.
"Closing the gap between the efficacy and effectiveness of MRAs in heart failure will require clinicians to address this issue. Quality improvement initiatives to improve appropriate laboratory monitoring are needed."
Source: The JAMA Network Journals
Articles on the same topic
- Common medication for heart failure patients does not increase activity levelThu, 12 Nov 2015, 20:06:37 UTC
- Effectiveness of drug to improve natriuretic peptide levels for chronic heart failureThu, 12 Nov 2015, 20:06:18 UTC
- Adults born with heart disease at increased risk of heart attack and deathTue, 10 Nov 2015, 0:37:00 UTC
- New study finds testosterone replacement therapy does not increase heart riskTue, 10 Nov 2015, 0:36:46 UTC
- Diabetes drug reduces risk of heart failure and may prevent it, study showsTue, 10 Nov 2015, 0:36:25 UTC
- Poor air quality increases patients' risk of heart attack, new study findsTue, 10 Nov 2015, 0:36:10 UTC
- Diagnosing & treating diabetes in heart attack patients improves heart outcomes, study findsTue, 10 Nov 2015, 0:35:39 UTC
- FIGHT study proves type-2 diabetes therapy ineffective in the treatment of high-risk heart failure patientsTue, 10 Nov 2015, 0:35:26 UTC
Other sources
- Firefighters Face Highest Heart Attack Risk Among Respondersfrom Live ScienceThu, 12 Nov 2015, 20:00:11 UTC
- Common medication for heart failure patients does not increase activity levelfrom Science DailyTue, 10 Nov 2015, 12:30:18 UTC
- Adults born with heart disease at increased risk of heart attack and deathfrom Science DailyTue, 10 Nov 2015, 4:30:33 UTC
- Long-term effects of wireless heart failure monitor just releasedfrom Science DailyTue, 10 Nov 2015, 3:47:05 UTC
- Diabetes drug reduces risk of heart failure and may prevent it, study showsfrom Science DailyTue, 10 Nov 2015, 2:40:38 UTC
- Effectiveness of drug to improve natriuretic peptide levels for chronic heart failurefrom Science DailyTue, 10 Nov 2015, 0:15:18 UTC
- FIGHT study demonstrates type-2 diabetes therapy ineffective in the treatment of high-risk heart failure patientsfrom Science DailyTue, 10 Nov 2015, 0:15:02 UTC
- Diagnosing and treating diabetes in heart attack patients improves heart outcomesfrom Science DailyMon, 9 Nov 2015, 23:30:09 UTC
- Ask Well: What Is the Link Between Depression and Heart Disease?from NY Times HealthMon, 9 Nov 2015, 9:37:24 UTC
- Poor air quality increases patients' risk of heart attackfrom Science DailyMon, 9 Nov 2015, 9:26:10 UTC
- Low rate of patient monitoring found following initiation of therapy for heart failurefrom Science DailyMon, 9 Nov 2015, 9:26:04 UTC